Voyager Therapeutics Cash on Hand 2014-2022 | VYGR

Voyager Therapeutics cash on hand from 2014 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Voyager Therapeutics Annual Cash on Hand
(Millions of US $)
2021 $133
2020 $181
2019 $282
2018 $156
2017 $169
2016 $174
2015 $194
2014 $7
2013 $0
Voyager Therapeutics Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $167
2021-12-31 $133
2021-09-30 $121
2021-06-30 $143
2021-03-31 $162
2020-12-31 $181
2020-09-30 $200
2020-06-30 $230
2020-03-31 $251
2019-12-31 $282
2019-09-30 $307
2019-06-30 $327
2019-03-31 $358
2018-12-31 $156
2018-09-30 $180
2018-06-30 $196
2018-03-31 $218
2017-12-31 $169
2017-09-30 $126
2017-06-30 $141
2017-03-31 $158
2016-12-31 $174
2016-09-30 $191
2016-06-30 $204
2016-03-31 $204
2015-12-31 $194
2015-09-30 $108
2015-06-30
2015-03-31
2014-12-31 $7
2014-09-30
2014-06-30
2014-03-31
2013-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.233B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00